The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19
Open Access
- 30 September 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 595739
- https://doi.org/10.3389/fimmu.2020.595739
Abstract
Type I interferons (IFN-I) were first discovered over 60 years ago in a classical experiment by Isaacs and Lindenman, who showed that IFN-Is possess antiviral activity. Later, it became one of the first approved protein drugs using heterologous protein expression systems, which allowed its large-scale production. It has been approved, and widely used in a pleiotropy of diseases, including multiple-sclerosis, hepatitis B and C, and some forms of cancer. Preliminary clinical data has supported its effectiveness against potential pandemic pathogens such as Ebola and SARS. Still, more efficient and specific drugs have taken its place in treating such diseases. The COVID-19 global pandemic has again lifted the status of IFN-Is to become one of the more promising drug candidates, with initial clinical trials showing promising results in reducing the severity and duration of the disease. Although SARS-CoV-2 inhibits the production of IFNβ and thus obstructs the innate immune response to this virus, it is sensitive to the antiviral activity of externally administrated IFN-Is. In this review I discuss the diverse modes of biological actions of IFN-Is and how these are related to biophysical parameters of IFN-I–receptor interaction and cell-type specificity in light of the large variety of binding affinities of the different IFN-I subtypes towards the common interferon receptor. Furthermore, I discuss how these may guide the optimized use IFN-Is in combatting COVID-19.Keywords
Funding Information
- Israel Academy of Sciences and Humanities
This publication has 121 references indexed in Scilit:
- Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosisThe Pharmacogenomics Journal, 2012
- Sensing of RNA Viruses: a Review of Innate Immune Receptors Involved in Recognizing RNA Virus InvasionJournal of Virology, 2012
- Interferons in Autoimmune and Inflammatory Diseases: Regulation and RolesJournal of Interferon & Cytokine Research, 2011
- Stochastic Receptor Expression Determines Cell Fate upon Interferon TreatmentMolecular and Cellular Biology, 2011
- Structural Linkage between Ligand Discrimination and Receptor Activation by Type I InterferonsCell, 2011
- STAT-Phosphorylation–Independent Induction of Interferon Regulatory Factor-9 by Interferon-βJournal of Interferon & Cytokine Research, 2010
- Dynamic Innate Immune Responses of Human Bronchial Epithelial Cells to Severe Acute Respiratory Syndrome-Associated Coronavirus InfectionPLOS ONE, 2010
- INTERFEROME: the database of interferon regulated genesNucleic Acids Research, 2008
- Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi MembraneJournal of Virology, 2007
- SARS: Systematic Review of Treatment EffectsPLoS Medicine, 2006